Beyond Air Inc. specializes in innovative nitric oxide (NO) therapies, primarily through its LungFit product family, which utilizes patented Ionizer™ technology to generate nitric oxide on-demand from room air. This technology eliminates the need for cumbersome gas cylinders, making it easier to administer treatments in various settings, including hospitals and at home. The LungFit systems are designed to provide both low-concentration inhaled nitric oxide (≤80 ppm) for neonatal care, specifically for conditions like persistent pulmonary hypertension of the newborn, and high-concentration inhaled nitric oxide (80 to 400 ppm) for treating community-acquired viral pneumonia, including COVID-19, and lung infections in patients with chronic obstructive pulmonary disease (COPD).

Beyond Air's commitment to advancing nitric oxide therapy is evident in its robust pipeline of products targeting respiratory conditions, cancer, and autism spectrum disorder. The company has a legacy of innovation, being led by the original inventors of the first nitric oxide delivery systems. Their approach not only enhances patient care by simplifying the treatment process but also improves operational efficiency for healthcare providers by reducing the logistical challenges associated with traditional nitric oxide delivery methods. With ongoing clinical trials and collaborations, Beyond Air aims to expand the accessibility and effectiveness of nitric oxide therapies across various medical applications.

United States

Beyond Air Inc. is a commercial stage medical device and biopharmaceutical company focused on harnessing nitric oxide therapy. The company is built on a legacy of innovation and is revolutionizing nitric oxide therapy. Beyond Air Inc. has experience and leadership that go beyond, with a team of industry professionals dedicated to advancing medical treatment. For more information, visit https://www.beyondair.net/

Beyond Air Inc.

Company Details